Neuranics

Neuranics is the first-ever joint spinout from the University of Glasgow and the University of Edinburgh, founded in 2021 to commercialise breakthrough spintronic magnetic sensing technology originally developed across both institutions. The company addresses a fundamental limitation in health monitoring and human-machine interaction: existing methods of measuring magnetic signals from the body require large, complex, expensive, lab-based equipment that cannot be miniaturised or worn. Neuranics' patented chip-scale sensors use scalable spintronics to detect tiny magnetic signals from organs — such as the heart and forearm muscles — at room temperature, in a low-power, low-cost package that can be integrated directly into wearable devices.

The company's core product is a Tunnelling Magnetoresistance (TMR) sensing platform that enables two breakthrough applications: magnetocardiography (MCG), which monitors cardiac signals without electrodes on the skin, and magnetomyography (MMG), which tracks individual finger movements by reading muscle magnetic activity for gesture recognition. These capabilities position Neuranics at the intersection of three high-growth markets: extended reality (XR) hardware, wearable health monitoring, and digital health. The company is actively collaborating with world-leading Tier-1 semiconductor and XR manufacturers to validate its TMR technology for high-volume commercial applications.

Neuranics raised a £1.9 million pre-seed round in 2023 led by Par Equity, followed by an $8 million seed round in April 2025 led by Blackfinch Ventures, with continued support from Archangels, Par Equity, Old College Capital, and the University of Glasgow. The company has won a prestigious CES Innovation Award and been selected for the 2026 Scale Up Scotland 2.0 programme, reflecting its standing as one of the UK's most exciting deep-tech semiconductor companies.